The 14 references in paper , , , , , Е. Тавлуева В., А. Ярковская П., А. Алексеенко В., Т. Пенская Ю., О. Барбараш Л. (2016) “ГИПОАГРЕГАЦИОННЫЙ ЭФФЕКТ У БОЛЬНЫХ ИНФАРКТОМ МИОКАРДА С ПОДЪЕМОМ СЕГМЕНТА ST ПРИ ЗАМЕНЕ КЛОПИДОГРЕЛА НА ТИКАГРЕЛОР” / spz:neicon:aterotromboz:y:2016:i:2:p:54-60

1
Абугов С.А., Аверков О.В, Комаров А.Л., Панченко Е.П., Руда М.Я., Шахнович Р.М. и соавт. Выбор перорального антиагреганта для лечения острого коронарного синдрома. Неотложная кардиология,
(check this in PDF content)
2
14, 4: 11-15. 2. 2014 ASC/EACTS Guidelines on myocardial revascularization. The task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J, 2014,
(check this in PDF content)
3
2541-2619. 3. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 2009, 361: 1045-1057.
(check this in PDF content)
4
Cannon CP, Harrington RA, James S, Ardissino D, Becker RC, Emanuelsson H et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomized double-blind study. Lancet,2010, 375: 283-293.
(check this in PDF content)
5
Болдуева С.А., Облавицкий Д.В., Самохвалова М.В. Развитие инфаркта миокарда после изменения характера двойной антиагрегантной терапии. Клиническое наблюдение. Неотложная кардиология, 2014, 4: 16-20.
(check this in PDF content)
6
Аверков О.В. Двойная антитромбоцитарная терапия как долгосрочное вмешательство в рамках вторичной профилактики после инфаркта миокарда: фокус на тикагрелор. Conilium medicum, 2015, 5(17): 38-43.
(check this in PDF content)
7
Нечаева Г.И., Дрокина О.В., Фисун Н.Н. Cовременная антиагрегантная терапия: место тикагрелора в клинических рекомендациях. Лечащий врач, 2015, 3: 72-75.
(check this in PDF content)
8
Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.Eur Heart J,2006, 27(9): 1038–1047.
(check this in PDF content)
9
Lindholm D, Varenhorst C, Cannon CP, Harrington RA, Himmelmann A, Maya J et al. Ticagrelor versus clopidogrel in patient with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur Heart J, 2014, 35: 2083-2093.
(check this in PDF content)
10
Storey RF, Angiolillo DJ, Patil SB, Desai B, Ecob R, Husted S et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes. The PLATO (PLATelet inhibition and patient Outcomes) PLATELET Substudy.J Am Coll Cardiol, 2010, 56(18): 1456–1462.
(check this in PDF content)
11
Aradi D, Storey RF, Komocsi A, Trenk D, Gulba D, Kiss RG et al. on behalf of the working group on thrombosis of the European Society of Cardiology. Expert position paper on the role of platelet function testing in patient undergoing percutaneous coronary intervention. Eur Heart J, 2014, 35: 209-215.
(check this in PDF content)
12
Storey RF, Husted S, Harrington RA, Heptinstall S, Wilcox RG, Peters G et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.J Am Coll Cardiol, 2007, 50(19): 1852–1856.
(check this in PDF content)
13
Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET Study.Circulation, 2009, 120(25): 2577–2585.
(check this in PDF content)
14
Данилов И.П. Тромбоциты: новый взгляд на их роль в организме. Медицинские новости,2008, 9: 17-19.
(check this in PDF content)